Cargando…

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer

We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping. Thirteen patients with previously treated mCR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Cheng-Jen, Huang, Ching-Wen, Yeh, Yung-Sung, Tsai, Hsiang-Lin, Hu, Huang-Ming, Wu, I-Chen, Cheng, Tian-Lu, Wang, Jaw-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840952/ https://www.ncbi.nlm.nih.gov/pubmed/27938508 http://dx.doi.org/10.3727/97818823455816X14786040691928

Ejemplares similares

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
por: Ma, Cheng-Jen, et al.
Publicado: (2019)

FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping
por: Lu, Chien-Yu, et al.
Publicado: (2014)

Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer
por: Wang, Yang, et al.
Publicado: (2017)

Effect of the genetic mutant G71R in uridine diphosphate-glucuronosyltransferase 1A1 on the conjugation of bilirubin
por: Chen, Hong, et al.
Publicado: (2022)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant
por: Ciftci, H. S., et al.
Publicado: (2018)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities
por: Liu, Yan-Qing, et al.
Publicado: (2016)

Revisiting the Latency of Uridine Diphosphate-Glucuronosyltransferases (UGTs)—How Does the Endoplasmic Reticulum Membrane Influence Their Function?
por: Liu, Yuejian, et al.
Publicado: (2017)

Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity
por: Tziotou, Marianna, et al.
Publicado: (2014)

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2016)

Pharmacogenetics of uridine diphosphate glucuronosyltransferase (UGT2B7) genetic polymorphism on valproic acid pharmacokinetics in epilepsy
por: Munisamy, Murali, et al.
Publicado: (2014)

Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only
por: Li, Ching-Chun, et al.
Publicado: (2022)

Homology Modeling of Human Uridine-5′-diphosphate-glucuronosyltransferase 1A6 Reveals Insights into Factors Influencing Substrate and Cosubstrate Binding
por: Smith, Alexander D., et al.
Publicado: (2020)

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
por: Bettonte, Sara, et al.
Publicado: (2023)

The time-dependent effects of St John’s wort on cytochrome P450, uridine diphosphate-glucuronosyltransferase, glutathione S-transferase, and NAD(P)H-quinone oxidoreductase in mice
por: Yang, Jin-Fu, et al.
Publicado: (2017)

UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer
por: Miyata, Yoshinori, et al.
Publicado: (2015)

Enzymatic Redox Cascade for One-Pot Synthesis of Uridine 5′-Diphosphate Xylose from Uridine 5′-Diphosphate Glucose
por: Eixelsberger, Thomas, et al.
Publicado: (2014)

Uridine diphosphate-glucuronosyltransferase 2B15 D85Y gene polymorphism is associated with lower prostate cancer risk: a systematic review and meta-analysis
por: Zhong, Xiao, et al.
Publicado: (2017)

Correlations between polymorphisms in the uridine diphosphate-glucuronosyltransferase 1A and C-C motif chemokine receptor 5 genes and infection with the hepatitis B virus in three ethnic groups in China
por: Zhang, Chan, et al.
Publicado: (2017)

Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice
por: Ueng, Yune-Fang, et al.
Publicado: (2015)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

Crigler-Najjar syndrome type II in a Chinese boy resulting from three mutations in the bilirubin uridine 5′-diphosphate-glucuronosyltransferase (UGT1A1) gene and a family genetic analysis
por: Zheng, Bixia, et al.
Publicado: (2014)

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
por: Páez, David, et al.
Publicado: (2018)

The Uridine diphosphate (UDP)-glycosyltransferases (UGTs) superfamily: the role in tumor cell metabolism
por: Liu, Wenyu, et al.
Publicado: (2023)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Glucosylation of (±)-Menthol by Uridine-Diphosphate-Sugar Dependent Glucosyltransferases from Plants
por: Kurze, Elisabeth, et al.
Publicado: (2021)

Cell‐Free Multi‐Enzyme Synthesis and Purification of Uridine Diphosphate Galactose
por: Mahour, Reza, et al.
Publicado: (2021)

Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study
por: Tanaka, Toshihiro, et al.
Publicado: (2019)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
por: Chang, Tsung-Kun, et al.
Publicado: (2021)

Toxin ζ Reduces the ATP and Modulates the Uridine Diphosphate-N-acetylglucosamine Pool
por: Moreno-del Álamo, María, et al.
Publicado: (2019)

Biosynthesis of uridine diphosphate N‐Acetylglucosamine: An underexploited pathway in the search for novel antibiotics?
por: Wyllie, Jessica A., et al.
Publicado: (2022)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients
por: Ando, Maki, et al.
Publicado: (2002)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
por: Masuishi, Toshiki, et al.
Publicado: (2023)

An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness
por: Tsai, Hsiang-Lin, et al.
Publicado: (2019)

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates
por: Reddy, Micaela B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_inra362llq932li9eombko4dmt